Company intelligence / Profile preview

Pharmaxon

Budapest, Hungary

Ownership: Private
Development stage: Other

Overview

PharmaXon is a biotechnology company focused on the discovery and development of small molecule therapeutics targeting the P2X7 receptor. The company's research centers on the role of purinergic signaling in neuroinflammation and its contribution to various central nervous system (CNS) and inflammatory disorders. PharmaXon's lead candidate, PX-17, is being developed for indications including neuropathic pain and treatment-resistant depression. The company aims to address significant unmet medical needs by modulating the P2X7 pathway to reduce the release of pro-inflammatory cytokines like IL-1β. PharmaXon was founded as a spin-off from the Institute of Experimental Medicine of the Hungarian Academy of Sciences.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Pharmaxon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmaxon.

Explore the full profile